<DOC>
	<DOCNO>NCT01944709</DOCNO>
	<brief_summary>The prognosis patient metastatic melanoma poor current available treatment limit . Identification number melanoma-specific tumor antigen share tumor different patient , provide attractive target immune-based therapy ( http : //www.bioinfo.org.cn/hptaa/ ) . Different approach like DNA-/RNA-vaccines , peptide vaccine dendritic cell ( DC ) vaccines investigation induce peptide-specific immune response . In various animal model clinical trial show potent induction anti tumor-specific killer cell achieve DC vaccination . DCs professional antigen present cell ( APC ) critical initiation cellular response na√Øve T lymphocyte , vivo . They arm molecule need induction immune response capacity migrate secondary lymphatic organ . In vitro generate dendritic cell load tumor derive peptide inject subcutaneously . The concept induce propagate already exist tumor specific killer T cell .</brief_summary>
	<brief_title>Phase I/II Study Vaccination With Antigen Loaded Dendritic Cells ( DCs ) Patients With Inoperable Stage III Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm melanoma Inoperable Stage III Stage IV melanoma Tumor expression MelanA and/or NYEso1 immunohistochemistry Human leukocyte antigen ( HLA ) A0201 positivity ( flow cytometry PCR ) Life expectancy three month Full recovery surgery Karnofsky scale performance status 70 % ( App II ) One prior chemo cytokine base therapy allow Age &gt; 18 year No uncontrolled infection Neutrophile count &gt; 1500/ul thrombocyte &gt; 100 000/ul Creatinine &lt; 1.5 upper normal level Adequate liver function bilirubin &lt; 2 upper normal level , alanine aminotransferase ( ALAT ) aspartate aminotransaminase ( ASAT ) &lt; 3 x upper normal level Clinically significant ( i.e . active ) cardiovascular disease : Cardiovascular accident ( CVA ) /stroke ( &lt; 6 month prior enrolment ) , myocardial infarction ( &lt; 6 month prior enrolment ) , unstable angina , congestive heart failure serious cardiac arrythmia require medication absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial patient registration , informed consent must give accord International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) , national/local regulation Presently clinically significant heart disease ( NYHA Class III IV ) Other serious illness , eg , serious infection require antibiotic , bleed disorder uncontrolled peptic ulcer , seizure central nervous system disorder History immunodeficiency disease severe autoimmune disease Metastatic disease central nervous system HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) ( test require ) severe uncontrolled infection Chemotherapy , radiation therapy , immunotherapy within 4 week study entry Concomitant treatment steroid antihistamine drug . Topical inhalational steroid permit Participation clinical trial involve another investigational agent within 6 week prior enrollment Pregnancy lactation Women childbearing potential use medically acceptable mean contraception Lack availability patient immunological clinical followup assessment . Coagulation bleed disorder Rapidly progress disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>melanoma</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>peptide</keyword>
	<keyword>Melan-A</keyword>
</DOC>